TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has no clinically significant findings on a physical examination and clinical laboratory tests~* Female patients of childbearing potential must agree to use one of the following methods of birth control:~  1. Hormonal contraception~ 2. Double-barrier birth control~ 3. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy~* Patient meets protocol criteria for diagnosis of IBS-C~* Patient demonstrates continued IBS-C symptoms through Pretreatment Period~* Patient maintains a minimum level of compliance with daily diary~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linaclotide 290 µg (Type: EXPERIMENTAL): Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients underwent to PCI~* lopidogrel resistance after Platelet reactivity blood test~Exclusion Criteria:~* history of bleeding diathesis~* chronic oral anticoagulation treatment~* contraindications to antiplatelet therapy~* PCI or coronary artery bypass grafting (CABG) \<3 months~* hemodynamic instability~* platelet count \<100,000/μl~* hematocrit \<30%~* creatinine clearance \<25 ml/min~* Patients with a history of stroke~* contraindication for prasugrel administration~* patients weighing \<60 kg~* \>75 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- high clopidogrel dose (Type: ACTIVE_COMPARATOR): Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
- prasugrel standard dose (Type: NO_INTERVENTION): Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have Class I and II indication for implantation of a dual chamber pacemaker according to the ACC/AHA/HRS guidelines~* Subjects who are able to undergo a pectoral implant~* Subjects who:~* are receiving an IPG for the first time, OR~* are receiving a replacement IPG connected to two previously- implanted (atrial and ventricular) Model 5076 leads~* Subjects who are able and willing to undergo elective MRI scanning without sedation~* Subjects who are geographically stable and available for follow-up at the study site for the length of the study~Exclusion Criteria:~* Subjects with a mechanical tricuspid heart valve.~* Subjects with a history of significant tricuspid valvular disease.~* Subjects for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated.~* Subjects who require a legally authorized representative to obtain consent.~* Subjects who have abandoned (inactive) pacemaker and/or defibrillator leads~* Subjects who are immediate candidates for an ICD.~* Subjects who require an indicated MRI scan, other than those specifically described in the study, before the one-month post MRI/waiting period follow-up.~* Subjects with previously implanted active medical devices (exception Model 5076 Lead and Advisa MRI IPG).~* Subjects with a non-MRI compatible device (such as ICDs or neurostimulators) or material implant (e.g., non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys).~* Subjects with medical conditions that preclude the testing required by the protocol or limit study participation.~* Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study.~* Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control.~* Subjects with exclusion criteria required by local law (e.g., age, breastfeeding).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI Group (Type: EXPERIMENTAL): Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
- Control Group (Type: SHAM_COMPARATOR): Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be greater than 14 days old and less than 5 years old~* Conjugated bilirubin greater than 2 mg/dL.~* Be expected to require intravenous nutrition for at least an additional 28 days~Exclusion Criteria:~* Have a congenitally lethal condition (e.g. Trisomy 13).~* Have clinically severe bleeding not able to be managed with routine measures.~* Have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis.~* Have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves.~Home Use of Omegaven®:~In order for a subject to receive the Omegaven® at home through a home health care agency, subjects will first be required to be admitted to Texas Children's Hospital for 72 hours in initiate the administration of the Omegaven®. This will allow time for observation of any unexpected side effects and for parents to be provided education on home TPN and Omegaven®.~If a subject has already received Omegaven® either at TCH or at another hospital, they will not be required to be admitted for the 72 hour inpatient admission prior to starting Omegaven® at home. Parent training will occur during the previous hospital admission and will continue through the TCH Pediatric Intestinal Rehabilitation Clinic.~Outpatient Monitoring:~After the initial evaluation by the TCH Pediatric Intestinal Rehabilitation Clinic physicians, subjects will return to the clinic for routine follow-up. Subjects will be asked to return to the clinic every 2 weeks for the first 2 months of treatment. Thereafter, subjects will return to the clinic on a monthly basis, or as directed by the clinic team.

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Fish Oil Emulsion Arm (Type: EXPERIMENTAL): In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants).~* Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600.~* Patients must have measurable disease defined by RECIST criteria 1.1.~* Tumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment.~* RAI-refractory disease on structural imaging~* Age ≥ 18 years.~* ECOG performance status ≤ 2~* Patients must have normal organ and marrow function as defined below:~  * Absolute neutrophil count (ANC) \> 1500/mcl~ * Hemoglobin ≥ 9 g/dL~ * Platelets ≥ 100,000/mcl~ * Albumin ≥ 2.5 g/dL~ * Total bilirubin ≤ 1.5x institutional ULN~ * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x institutional ULN unless it is related to the primary disease~ * Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min OR 24-hour urine creatinine clearance ≥ 50 mL/min~Exclusion Criteria:~* Concomitant malignancies or previous malignancies treated within the past 3 years. Exception: Patients who have been disease-free for 3 years, patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent secondary malignancies, are eligible.~* Use of other investigational drugs within 28 days preceding the first dose of vemurafenib on this study.~* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.~* History or evidence of cardiovascular risk including any of the following:~  * Corrected QT (QTc) interval ≥ 450 msec at baseline or history of congenital long QT syndrome or uncorrectable electrolyte abnormalities. (Patients with well controlled atrial fibrillation are exempt from this criteria.)~ * History of cerebrovascular attack or transient ischemic attack within 6 months prior to the initiation of therapy on this protocol.~ * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of Vemurafenib and KTN3379 (Type: EXPERIMENTAL): Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Written informed consent~* Endoscopically confirmed GERD (Los Angeles classification A-D)~* Patients whose compliance is expected to be high with respect to the completion of the questionnaires~Main Exclusion Criteria:~* Other gastrointestinal diseases~* Severe concomitant diseases~* Proton pump inhibitors (PPIs) during last 14 days before start~* H2 receptor antagonists, prokinetics during last 7 days before study start~* Helicobacter pylori (H. pylori) eradication during last 28 days before study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Two Different Techniques to Perform TAP-blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* We will recruit women undergoing scheduled cesarean delivery under neuraxial anesthesia~Exclusion Criteria:~* Age less than 18 years~* We will limit recruitment to women able to speak atleast one of the following languages: English, Spanish, Chinese, Russian~* Chronic pain syndrome~* Opioid dependence~* Allergy to local anesthetic~* Vertical skin incision~* Sepsis at the site of injection~* Converted to general anesthesia~* Any complicated procedures including blood loss more than 2000ml and duration of surgery more than 2 hours.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Surgical TAP block (Type: EXPERIMENTAL): surgeon administered intraoperative TAP block using 0.5% ropivacaine
- Conventional TAP block (Type: ACTIVE_COMPARATOR): Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 2 months (42 to 98 days) at the time of enrollment.~2. Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.~3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.~4. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.~Exclusion Criteria:~1. Previous vaccination with licensed or investigational pneumococcal vaccine.~2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccines.~3. A previous anaphylactic reaction to any vaccine or vaccine-related component.~4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, pneumococcal conjugate, or meningococcal conjugate vaccines.~5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~6. Known or suspected immune deficiency or suppression.~7. History of culture-proven invasive disease caused by S pneumoniae, Neisseria meningitidis, or Hib.~8. Major known congenital malformation or serious chronic disorder.~9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. This did not include resolving syndromes due to birth trauma such as Erb palsy.~10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis®).~11. Participation in another investigational trial. Participation in purely observational studies was acceptable.~12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 13-valent pneumococcal vaccine
- 2 (Type: ACTIVE_COMPARATOR): 7-valent pneumococcal vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a confirmed diagnosis consistent with idiopathic generalized epilepsy experiencing myoclonic seizures (IIB) that are classifiable according to the International Classification of Epileptic Seizures. To ensure an idiopathic generalized epilepsy population, only these subjects with the diagnosis of juvenile myoclonic epilepsy (JME), juvenile absence epilepsy (JAE) or epilepsy with generalized tonic- clonic seizures on awakening must be included.~* Presence of at least eight days with at least one myoclonic seizure (IIB) per day during the eight weeks of the Baseline period.~* Absence of brain lesion documented on a CT scan or MRI; if a CT scan or MRI has not been performed within the past five years before Visit 1, a CT scan (or MRI where legally required) should be performed during the Baseline period.~* Presence of EEG features consistent with idiopathic generalized epilepsy on an EEG recorded during the Baseline period or no more than one year before Visit 1.~* Male/female children ≥ 12 years of age or adult ≤ 65 years of age at Visit 1.~* Subject on a stable dose of one standard anti-epileptic treatment for at least four weeks before Visit 1.~Exclusion Criteria:~* Previous exposure to levetiracetam.~* History of partial seizures.~* History of convulsive or non-convulsive status epilepticus within 3 months prior to Visit 1.~* Subject taking vigabatrin or tiagabine, subject on felbamate with less than 18 months exposure, and subject under vagal nerve stimulation or ketogenic diet.~* Subject taking any drug (except the concomitant AEDs) with possible CNS effects.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients living independently in residential homes for the elderly or day patients)~* have mild to moderate dementia, as evidenced by a Mini-Mental Status Examination (MMSE) score of 11 - 24, and a score of at least 12 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog)~* history of at least a 6 months of gradual and progressive cognitive decline~* have a consistent informant to accompany the patient on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* dementia caused by small strokes or cerebrovascular disease~* cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor~* having epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease~* females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete